We are live on
!
Find out more
KAM
Kazazian Asset Management Portfolio holdings
AUM
$91.5M
1-Year Est. Return
35.36%
This Fund
S&P 500
This Quarter
Est. Return
-3.92%
1 Year Est. Return
+35.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.4M
AUM Growth
-$2.44M
(-2.5%)
Cap. Flow
+$4.55M
Cap. Flow
% of AUM
4.76%
Top 10 Holdings %
Top 10 Hldgs %
49.5%
Holding
93
New
11
Increased
17
Reduced
38
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
|
+$2.15M |
| 2 |
Biogen
BIIB
|
+$1.77M |
| 3 |
Intel
INTC
|
+$1.21M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$993K |
| 5 |
Oracle
ORCL
|
+$903K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$976K |
| 2 |
PPLI
People Inc
PPLI
|
+$900K |
| 3 |
Micron Technology
MU
|
+$884K |
| 4 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$836K |
| 5 |
General Motors
GM
|
+$688K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.25% |
| 2 | Consumer Discretionary | 9.29% |
| 3 | Financials | 8.39% |
| 4 | Technology | 6.79% |
| 5 | Communication Services | 5.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
26
DELISTED
Aerie Pharmaceuticals
AERI
| $994K | 1.04% |
18,321
+5,855
| +47% | +$327K |
|
27
VanEck Gold Miners ETF
GDX
$27.4B
| $876K | 0.92% |
39,860
-1,736
| -4% | -$39.2K |
|
|
EIGI
28
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $861K | 0.9% |
116,347
+77,386
| +199% | +$615K |
|
|
29
Oracle
ORCL
$423B
| $831K | 0.87% |
+18,160
| New | +$903K |
|
30
Aurinia Pharmaceuticals
AUPH
$2.11B
| $810K | 0.85% |
156,126
| – | – |
|
31
iShares Biotechnology ETF
IBB
$9.71B
| $801K | 0.84% |
+7,500
| New | +$831K |
|
|
BLUE
32
DELISTED
bluebird bio
BLUE
| $778K | 0.82% |
352
| – | – |
|
33
Expedia Group
EXPE
$37.3B
| $742K | 0.78% |
6,719
-681
| -9% | -$79.3K |
|
34
Merck
MRK
$318B
| $653K | 0.68% |
12,568
| – | – |
|
|
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
| $652K | 0.68% |
16,268
| – | – |
|
36
Targa Resources
TRGP
$55.1B
| $647K | 0.68% |
+14,709
| New | +$701K |
|
37
Abbott
ABT
$187B
| $640K | 0.67% |
10,688
| – | – |
|
|
TSRO
38
DELISTED
TESARO, Inc.
TSRO
| $595K | 0.62% |
10,408
+2,602
| +33% | +$167K |
|
|
GBT
39
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $566K | 0.59% |
11,711
-7,805
| -40% | -$435K |
|
|
PTLA
40
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $552K | 0.58% |
16,910
+3,253
| +24% | +$143K |
|
|
SPPI
41
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $523K | 0.55% |
32,526
| – | – |
|
42
GSK
GSK
$106B
| $508K | 0.53% |
10,409
| – | – |
|
43
Chipotle Mexican Grill
CMG
$41.5B
| $496K | 0.52% |
76,800
-7,400
| -9% | -$46.6K |
|
|
NETI
44
DELISTED
Eneti Inc.
NETI
| $493K | 0.52% |
7,530
-448
| -6% | -$32.1K |
|
45
Incyte
INCY
$24.4B
| $488K | 0.51% |
5,856
+1,301
| +29% | +$117K |
|
46
Puma Biotechnology
PBYI
$454M
| $487K | 0.51% |
7,157
+2,602
| +57% | +$195K |
|
|
CXO
47
DELISTED
CONCHO RESOURCES INC.
CXO
| $468K | 0.49% |
3,111
-314
| -9% | -$47.9K |
|
|
LJPC
48
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $462K | 0.48% |
15,516
+3,253
| +27% | +$105K |
|
|
DO
49
DELISTED
Diamond Offshore Drilling
DO
| $456K | 0.48% |
31,102
-3,136
| -9% | -$51.8K |
|
50
AstraZeneca
AZN
$250B
| $455K | 0.48% |
6,506
| – | – |
|
Similar funds
MRP
ITG
MA
AW
SPCM
ML
ICM
ACMC
Kazazian Asset Management's Q1 2018 Portfolio in Review
As of Q1 2018, Kazazian Asset Management held 93 positions worth $95.4M, down 2.5% from $97.9M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Kazazian Asset Management deployed $4.55M of net new capital in Q1 2018, opening 11 new positions and adding to 17 existing holdings. Its largest new stake was State Street SPDR S&P Oil & Gas Exploration & Production ETF: 15,000 shares worth $2.11M.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was General Motors, an estimated $688K trimmed.
- Kazazian Asset Management's largest Q1 2018 buy was State Street SPDR S&P Oil & Gas Exploration & Production ETF: 15,000 shares worth $2.11M.
- Kazazian Asset Management added most to Biogen in Q1 2018, an estimated $1.77M increase.
- Kazazian Asset Management's biggest Q1 2018 reduction was General Motors, cutting an estimated $688K.
- Kazazian Asset Management fully exited Vertex Pharmaceuticals in Q1 2018, selling an estimated $976K.
- Kazazian Asset Management's ten largest holdings make up 50% of its $95.4M portfolio in Q1 2018.
- Kazazian Asset Management opened 11 new positions and closed 8 in Q1 2018.
- Kazazian Asset Management's portfolio value fell 2.5% quarter-over-quarter to $95.4M.
Based on Kazazian Asset Management's 13F filing for Q1 2018, filed 15 May 2018.